Drawing for SINDU PHARMACEUTICALS

USPTO serial 78638080

SINDU PHARMACEUTICALS

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
RAUEN, JAMES
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SINDU PHARMACEUTICALS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jeffrey D. Hsi

Jeffrey D. Hsi Edwards Angell Palmer & Dodge LLPP.O. Box 130F.D.R. StationNew York, NY 10150

Goods and services

ClassDescriptionStatusFirst use
005pharmaceutical products intended for the treatment of infectious diseases, namely, bacterial, fungal, parasitic and viral infections, neoplastic disorders namely, hematologic cancer disorders and solid tumors, autoimmune disorders, namely, diabetes, arthritis, psoriasis, bone marrow and organ transplantation and immunosuppression, metabolic disorders namely, obesity and atherosclerosis, cardiovascular disorders namely, hypertension, congestive heart failure, myocardial infarction, angina and vascular diseases, renal disorders namely, acute and chronic renal failure and urinary disorders affecting renal conservation of water, central nervous system disorders namely, analgesia, anesthesia, hypnotics, sedatives, anxiety, psychosis, depression, mania, epilepsies, migraine, neurodegeneration, and drug addiction, inflammatory disorders namely, asthma, gout, inflammatory bowel disease, rheumatoid arthritis, gastrointestinal disorders namely, ulcers, emesis, diarrhea, irritable bowel syndrome, hormonal disorders affecting the thyroid, estrogens, progestins, androgens, glucocorticoids, insulin and glucose regulation, calcification and bone turnover, dermatological and opthalmological disordersACTIVE—
042pharmaceutical drug development services of pharmaceutical products intended for the treatment of infectious diseases, namely, bacterial, fungal, parasitic and viral infections, neoplastic disorders namely, hematologic cancer disorders and solid tumors, autoimmune disorders, namely, diabetes, arthritis, psoriasis, bone marrow and organ transplantation and immunosuppression, metabolic disorders namely, obesity and atherosclerosis, cardiovascular disorders namely, hypertension, congestive heart failure, myocardial infarction, angina and vascular diseases, renal disorders namely, acute and chronic renal failure and urinary disorders affecting renal conservation of water, central nervous system disorders namely, analgesia, anesthesia, hypnotics, sedatives, anxiety, psychosis, depression, mania, epilepsies, migraine, neurodegeneration, and drug addiction, inflammatory disorders namely, asthma, gout, inflammatory bowel disease, rheumatoid arthritis, gastrointestinal disorders namely, ulcers, emesis, diarrhea, irritable bowel syndrome, hormonal disorders affecting the thyroid, estrogens, progestins, androgens, glucocorticoids, insulin and glucose regulation, calcification and bone turnover, dermatological and opthalmological disordersACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jun 8, 2009MAB6ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 8, 2009ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Nov 7, 2008EX5GSOU EXTENSION 5 GRANTED—
Nov 7, 2008EXT5SOU EXTENSION 5 FILED—
Nov 7, 2008EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 9, 2008EX4GSOU EXTENSION 4 GRANTED—
May 9, 2008EXT4SOU EXTENSION 4 FILED—
May 9, 2008EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 6, 2007EX3GSOU EXTENSION 3 GRANTED—
Nov 6, 2007EXT3SOU EXTENSION 3 FILED—
Nov 6, 2007EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 26, 2007EX2GSOU EXTENSION 2 GRANTED—
Apr 26, 2007EXT2SOU EXTENSION 2 FILED—
Apr 26, 2007EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Nov 9, 2006EX1GSOU EXTENSION 1 GRANTED—
Nov 9, 2006EXT1SOU EXTENSION 1 FILED—
Nov 9, 2006EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
May 9, 2006NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Feb 14, 2006PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jan 25, 2006NPUBNOTICE OF PUBLICATION—
Jan 4, 2006PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Dec 30, 2005ALIEASSIGNED TO LIE—
Dec 20, 2005CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Dec 20, 2005XAECEXAMINER'S AMENDMENT ENTERED—
Dec 20, 2005GNEAEXAMINERS AMENDMENT E-MAILED—
Dec 20, 2005CNEAEXAMINERS AMENDMENT -WRITTEN—
Dec 19, 2005DOCKASSIGNED TO EXAMINER—
Jun 6, 2005NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance